Key Segmentation
By Biomarker
-
Circulating Tumour DNA
-
Circulating Tumour Cells
-
Exosomes/Extracellular Vesicles
-
Others
By Technology
-
PCR-Based
-
NGS
-
Digital PCR
-
Others
By Application
-
Cancer
-
Reproductive Health
-
Transplantation
-
Others
By End User
-
Hospitals & Laboratories
-
Research Institutes
-
Pharmaceutical & Biotech Companies
-
Others
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market player
Frequently Asked Questions
The Liquid Biopsy Market is expected to grow at a CAGR of 19.12% from 2026 to 2035.
The Liquid Biopsy Market was valued at USD 6.39 Billion in 2025.
Rising global cancer incidence creating clinical demand across diagnosis, treatment selection, monitoring, and recurrence surveillance, FDA companion diagnostic approvals creating insurance reimbursement pathways that sustain routine clinical adoption, and multi-cancer early detection technology commercially validating liquid biopsy’s population screening potential.
Cancer dominated the Liquid Biopsy Market with 86.46% share in 2025.
North America dominated the Liquid Biopsy Market in 2025 with 52.3% revenue share, with the United States accounting for approximately 87.4% of North American revenues.